{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:38:51Z","timestamp":1789263531808,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["12055"],"award-info":[{"award-number":["12055"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["12055"],"award-info":[{"award-number":["12055"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["12055"],"award-info":[{"award-number":["12055"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with peritoneal metastases (PM) of colorectal cancer have a very poor outcome. Intraperitoneal delivery of chemotherapy is the preferred route for PM treatment. The main limitation of the treatment options is the short residence time of the cytostatic, with subsequent short exposure of the cancer cells. To address this, a supramolecular hydrogel has been developed that allows both local and slow release of its encapsulated drug, mitomycin C (MMC) or cholesterol-conjugated MMC (cMMC), respectively. This experimental study investigates if drug delivery using this hydrogel improves the therapeutic efficacy against PM. PM was induced in WAG\/Rij rats (n\u2009=\u200972) by intraperitoneally injecting syngeneic colon carcinoma cells (CC531) expressing luciferase. After seven days, animals received a single intraperitoneal injection with saline (n\u2009=\u20098), unloaded hydrogel (n\u2009=\u200912), free MMC (n\u2009=\u200913), free cMMC (n\u2009=\u200913), MMC-loaded hydrogel (n\u2009=\u200913), or cMMC-loaded hydrogel (n\u2009=\u200913). Primary outcome was overall survival with a maximum follow-up of 120 days. Intraperitoneal tumor development was non-invasive monitored via bioluminescence imaging. Sixty-one rats successfully underwent all study procedures and were included to assess therapeutic efficacy. After 120 days, the overall survival in the MMC-loaded hydrogel and free MMC group was 78% and 38%, respectively. A trend toward significance was found when comparing the survival curves of the MMC-loaded hydrogel and free MMC (p\u2009=\u20090.087). No survival benefit was found for the cMMC-loaded hydrogel compared to free cMMC. Treating PM with our MMC-loaded hydrogel, exhibiting prolonged MMC exposure, seems effective in improving survival compared to treatment with free MMC.<\/jats:p>","DOI":"10.1007\/s10585-023-10210-0","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T02:01:22Z","timestamp":1684720882000},"page":"243-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Treating colorectal peritoneal metastases with an injectable cytostatic loaded supramolecular hydrogel in a rodent animal model"],"prefix":"10.1007","volume":"40","author":[{"given":"Anne G. W. E.","family":"Wintjens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter-Paul K.H.","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaatje","family":"Lenaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert C.","family":"van Almen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion J.","family":"Gijbels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u2019hamed","family":"Hadfoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas T.C.","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasja G.","family":"Lieuwes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne","family":"Biemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig J.","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Y.W.","family":"Dankers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace H.J.T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole D.","family":"Bouvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"issue":"2","key":"10210_CR1","first-page":"89","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Barsouk A (2019) Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol 14(2):89\u2013103","journal-title":"Prz Gastroenterol"},{"issue":"10","key":"10210_CR2","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.tranon.2021.101174","volume":"14","author":"Y Xi","year":"2021","unstructured":"Xi Y, Xu P (2021) Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 14(10):101174","journal-title":"Transl Oncol"},{"issue":"41","key":"10210_CR3","doi-asserted-by":"publisher","first-page":"11767","DOI":"10.3748\/wjg.v21.i41.11767","volume":"21","author":"S Vatandoust","year":"2015","unstructured":"Vatandoust S, Price TJ, Karapetis CS (2015) Colorectal cancer: metastases to a single organ. World J Gastroenterol 21(41):11767\u201311776","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10210_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000454687","volume":"33","author":"JW Holch","year":"2017","unstructured":"Holch JW, Demmer M, Lamersdorf C, Michl M, Schulz C, von Einem JC et al (2017) Pattern and Dynamics of Distant Metastases in metastatic colorectal Cancer. Visc Med 33(1):70\u201375","journal-title":"Visc Med"},{"key":"10210_CR5","unstructured":"Desai JP, Moustarah F (2022) Peritoneal metastasis. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2022. StatPearls Publishing LLC."},{"issue":"12","key":"10210_CR6","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT et al (2016) Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the Digestive System (ARCAD) database. Lancet Oncol 17(12):1709\u20131719","journal-title":"Lancet Oncol"},{"issue":"1","key":"10210_CR7","doi-asserted-by":"publisher","first-page":"20180102","DOI":"10.1515\/pp-2018-0102","volume":"3","author":"J Franko","year":"2018","unstructured":"Franko J (2018) Therapeutic efficacy of systemic therapy for colorectal peritoneal carcinomatosis: Surgeon\u2019s perspective. Pleura Peritoneum 3(1):20180102","journal-title":"Pleura Peritoneum"},{"key":"10210_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejca.2016.07.002","volume":"65","author":"LG Razenberg","year":"2016","unstructured":"Razenberg LG, Lemmens VE, Verwaal VJ, Punt CJ, Tanis PJ, Creemers GJ et al (2016) Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: results of a population-based study. Eur J Cancer 65:113\u2013120","journal-title":"Eur J Cancer"},{"issue":"3","key":"10210_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","volume":"30","author":"J Franko","year":"2012","unstructured":"Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM et al (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30(3):263\u2013267","journal-title":"J Clin Oncol"},{"issue":"1","key":"10210_CR10","first-page":"45","volume":"7","author":"MD Goodman","year":"2016","unstructured":"Goodman MD, McPartland S, Detelich D, Saif MW (2016) Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol 7(1):45\u201357","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"10210_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1515\/pp-2017-0010","volume":"2","author":"E de Bree","year":"2017","unstructured":"de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O (2017) Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum 2(2):47\u201362","journal-title":"Pleura Peritoneum"},{"issue":"1","key":"10210_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12885-019-5545-0","volume":"19","author":"KP Rovers","year":"2019","unstructured":"Rovers KP, Bakkers C, Simkens G, Burger JWA, Nienhuijs SW, Creemers GM et al (2019) Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer 19(1):390","journal-title":"BMC Cancer"},{"issue":"20","key":"10210_CR13","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737\u20133743","journal-title":"J Clin Oncol"},{"issue":"24","key":"10210_CR14","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1002\/cncr.25356","volume":"116","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L et al (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116(24):5608\u20135618","journal-title":"Cancer"},{"issue":"2","key":"10210_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, Go\u00e9r\u00e9 D, Ghouti L, Pocard M et al (2021) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22(2):256\u2013266","journal-title":"Lancet Oncol"},{"key":"10210_CR16","doi-asserted-by":"crossref","first-page":"720858","DOI":"10.1155\/2013\/720858","volume":"2013","author":"L De Smet","year":"2013","unstructured":"De Smet L, Ceelen W, Remon JP, Vervaet C (2013) Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. ScientificWorldJournal 2013:720858","journal-title":"ScientificWorldJournal"},{"issue":"4","key":"10210_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10585-022-10173-8","volume":"39","author":"A Wintjens","year":"2022","unstructured":"Wintjens A, Simkens GA, Fransen PKH, Serafras N, Lenaerts K, Franssen G et al (2022) Intraperitoneal drug delivery systems releasing cytostatic agents to target gastro-intestinal peritoneal metastases in laboratory animals: a systematic review. Clin Exp Metastasis 39(4):541\u2013579","journal-title":"Clin Exp Metastasis"},{"key":"10210_CR18","doi-asserted-by":"crossref","unstructured":"Wintjens AGWE, Fransen PKH, Lenaerts K, Liu H, van Almen GC, van Steensel S et al (2023) Development of a Supramolecular Hydrogel for Intraperitoneal Injections.Macromol Biosci. :e2300005","DOI":"10.1002\/mabi.202300005"},{"issue":"17","key":"10210_CR19","doi-asserted-by":"publisher","first-page":"1800007","DOI":"10.1002\/marc.201800007","volume":"39","author":"MH Bakker","year":"2018","unstructured":"Bakker MH, Grillaud M, Wu DJ, Fransen P-PKH, de Hingh IH, Dankers PYW (2018) Cholesterol modification of an Anticancer drug for efficient incorporation into a Supramolecular Hydrogel System. Macromol Rapid Commun 39(17):1800007","journal-title":"Macromol Rapid Commun"},{"issue":"22","key":"10210_CR20","doi-asserted-by":"publisher","first-page":"14052","DOI":"10.1039\/D2RA00346E","volume":"12","author":"MJG Schotman","year":"2022","unstructured":"Schotman MJG, Fransen P-P, Song J, Dankers PYW (2022) Tuning the affinity of amphiphilic guest molecules in a supramolecular polymer transient network. RSC Adv 12(22):14052\u201314060","journal-title":"RSC Adv"},{"issue":"4","key":"10210_CR21","first-page":"1260","volume":"26","author":"J Spiliotis","year":"2021","unstructured":"Spiliotis J, Kalles V, Prodromidou A, Raptis A, Ferfelis M, Christopoulou A et al (2021) Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis. J buon 26(4):1260\u20131265","journal-title":"J buon"},{"issue":"1","key":"10210_CR22","first-page":"15","volume":"38","author":"K Murono","year":"2018","unstructured":"Murono K, Kawai K, Hata K, Emoto S, Kaneko M, Sasaki K et al (2018) Regimens of intraperitoneal chemotherapy for peritoneal carcinomatosis from Colorectal Cancer. Anticancer Res 38(1):15\u201322","journal-title":"Anticancer Res"},{"issue":"19","key":"10210_CR23","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1021\/ja500205v","volume":"136","author":"M Guo","year":"2014","unstructured":"Guo M, Pitet LM, Wyss HM, Vos M, Dankers PYW, Meijer EW (2014) Tough stimuli-responsive Supramolecular Hydrogels with Hydrogen-Bonding Network Junctions. J Am Chem Soc 136(19):6969\u20136977","journal-title":"J Am Chem Soc"},{"key":"10210_CR24","doi-asserted-by":"crossref","unstructured":"Mollet BB, Spaans S, Fard PG, Bax NAM, Bouten CVC, Dankers PYW (2017) Mechanically robust Electrospun Hydrogel Scaffolds Crosslinked via Supramolecular interactions.Macromol Biosci. ; 17(9)","DOI":"10.1002\/mabi.201700053"},{"issue":"1","key":"10210_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1039\/C9BM01241A","volume":"8","author":"M Putti","year":"2020","unstructured":"Putti M, Mes T, Huang J, Bosman AW, Dankers PYW (2020) Multi-component supramolecular fibers with elastomeric properties and controlled drug release. Biomaterials Sci 8(1):163\u2013173","journal-title":"Biomaterials Sci"},{"issue":"3","key":"10210_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1245\/s10434-011-1984-9","volume":"19","author":"YLB Klaver","year":"2012","unstructured":"Klaver YLB, Hendriks T, Lomme RMLM, Rutten HJT, Bleichrodt RP, de Hingh IHJT (2012) Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study. Ann Surg Oncol 19(3):475\u2013482","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10210_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1515\/pp-2016-0006","volume":"1","author":"F Gremonprez","year":"2016","unstructured":"Gremonprez F, Willaert W, Ceelen W (2016) Animal models of colorectal peritoneal metastasis. Pleura Peritoneum 1(1):23\u201343","journal-title":"Pleura Peritoneum"},{"issue":"6","key":"10210_CR28","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3390\/cancers12061585","volume":"12","author":"AM Mowday","year":"2020","unstructured":"Mowday AM, Lieuwes NG, Biemans R, Marcus D, Rezaeifar B, Reniers B et al (2020) Use of a luciferase-expressing Orthotopic Rat Brain Tumor Model to optimize a targeted irradiation strategy for Efficacy Testing with Temozolomide. Cancers 12(6):1585","journal-title":"Cancers"},{"issue":"4","key":"10210_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1053\/ejso.2001.1117","volume":"27","author":"AMF Lopes Cardozo","year":"2001","unstructured":"Lopes Cardozo AMF, Gupta A, Koppe MJ, Meijer S, van Leeuwen PAM, Beelen RJH et al (2001) Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol (EJSO) 27(4):359\u2013363","journal-title":"Eur J Surg Oncol (EJSO)"},{"issue":"12","key":"10210_CR30","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/bjs.7249","volume":"97","author":"YL Klaver","year":"2010","unstructured":"Klaver YL, Hendriks T, Lomme RM, Rutten HJ, Bleichrodt RP, de Hingh IH (2010) Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for peritoneal carcinomatosis in an experimental model. Br J Surg 97(12):1874\u20131880","journal-title":"Br J Surg"},{"issue":"10","key":"10210_CR31","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1093\/annonc\/mdq762","volume":"22","author":"YL Klaver","year":"2011","unstructured":"Klaver YL, Lemmens VE, Creemers GJ, Rutten HJ, Nienhuijs SW, de Hingh IH (2011) Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol 22(10):2250\u20132256","journal-title":"Ann Oncol"},{"issue":"11","key":"10210_CR32","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1245\/s10434-007-9509-2","volume":"14","author":"F Aarts","year":"2007","unstructured":"Aarts F, Hendriks T, Boerman OC, Koppe MJ, Oyen WJG, Bleichrodt RP (2007) A comparison between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the treatment of peritoneal carcinomatosis of Colonic origin in rats. Ann Surg Oncol 14(11):3274\u20133282","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10210_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1515\/pp-2017-0003","volume":"2","author":"K Van der Speeten","year":"2017","unstructured":"Van der Speeten K, Lemoine L, Sugarbaker P (2017) Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice. Pleura Peritoneum 2(2):63\u201372","journal-title":"Pleura Peritoneum"},{"issue":"7","key":"10210_CR34","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F, Bakrin N, Villeneuve L, Laplace N et al (2019) Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 20(7):e368\u2013e77","journal-title":"Lancet Oncol"},{"issue":"2","key":"10210_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4251\/wjgo.v2.i2.109","volume":"2","author":"TD Yan","year":"2010","unstructured":"Yan TD, Cao CQ, Munkholm-Larsen S (2010) A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol 2(2):109\u2013116","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"10210_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jconrel.2012.03.008","volume":"158","author":"K Park","year":"2012","unstructured":"Park K (2012) Intraperitoneal delivery of paclitaxel with injectable hydrogel: \u201cSeeing\u201d is not always \u201cbelieving. J Controlled Release 158(3):355","journal-title":"J Controlled Release"},{"issue":"1","key":"10210_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/1471-2407-10-402","volume":"10","author":"Y Wang","year":"2010","unstructured":"Wang Y, Gong C, Yang L, Wu Q, Shi S, Shi H et al (2010) 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice. BMC Cancer 10(1):402","journal-title":"BMC Cancer"},{"issue":"5","key":"10210_CR38","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1440-1746.2009.06155.x","volume":"25","author":"GP Wang","year":"2010","unstructured":"Wang GP, Guan YS, Jin XR, Jiang SS, Lu ZJ, Wu Y et al (2010) Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites. J Gastroenterol Hepatol 25(5):985\u2013990","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10210_CR39","doi-asserted-by":"publisher","first-page":"e98455","DOI":"10.1371\/journal.pone.0098455","volume":"9","author":"Q Tang","year":"2014","unstructured":"Tang Q, Wang Y, Huang R, You Q, Wang G, Chen Y et al (2014) Preparation of anti-tumor nanoparticle and its inhibition to peritoneal dissemination of colon cancer. PLoS ONE 9(6):e98455","journal-title":"PLoS ONE"},{"issue":"1","key":"10210_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00001813-199010000-00002","volume":"1","author":"J Verweij","year":"1990","unstructured":"Verweij J, Pinedo HM, Mitomycin C (1990) Mechanism of action, usefulness and limitations. Anticancer Drugs 1(1):5\u201313","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10210_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/PPO.0b013e3181a58d95","volume":"15","author":"K Van der Speeten","year":"2009","unstructured":"Van der Speeten K, Stuart OA, Sugarbaker PH (2009) Pharmacokinetics and pharmacodynamics of Perioperative Cancer Chemotherapy in Peritoneal Surface Malignancy. Cancer J 15(3):216\u2013224","journal-title":"Cancer J"},{"issue":"5","key":"10210_CR42","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/bjc.2015.18","volume":"112","author":"R Kwakman","year":"2015","unstructured":"Kwakman R, de Cuba EMV, de Winter JP, de Hingh IHJT, Delis-van Diemen PM, Tijssen M et al (2015) Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival. Br J Cancer 112(5):851\u2013856","journal-title":"Br J Cancer"},{"issue":"2","key":"10210_CR43","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/0090-8258(86)90097-1","volume":"25","author":"VK Malviya","year":"1986","unstructured":"Malviya VK, Young JD, Boike G, Gove N, Deppe G (1986) Pharmacokinetics of mitomycin-C in plasma and tumor tissue of cervical cancer patients and in selected tissues of female rats. Gynecol Oncol 25(2):160\u2013170","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10210_CR44","doi-asserted-by":"publisher","first-page":"9467","DOI":"10.1002\/anie.202015362","volume":"60","author":"S Jangra","year":"2021","unstructured":"Jangra S, De Vrieze J, Choi A, Rathnasinghe R, Laghlali G, Uvyn A et al (2021) Sterilizing immunity against SARS-CoV-2 infection in mice by a single-shot and lipid amphiphile Imidazoquinoline TLR7\/8 agonist-adjuvanted recombinant spike protein Vaccine**. Angew Chem Int Ed 60(17):9467\u20139473","journal-title":"Angew Chem Int Ed"},{"issue":"43","key":"10210_CR45","doi-asserted-by":"publisher","first-page":"15390","DOI":"10.1002\/anie.201905687","volume":"58","author":"J De Vrieze","year":"2019","unstructured":"De Vrieze J, Louage B, Deswarte K, Zhong Z, De Coen R, Van Herck S et al (2019) Potent lymphatic translocation and spatial control over Innate Immune activation by polymer\u2013lipid Amphiphile Conjugates of small-molecule TLR7\/8 agonists. Angew Chem Int Ed 58(43):15390\u201315395","journal-title":"Angew Chem Int Ed"},{"issue":"6","key":"10210_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.0959-9673.2005.00452.x","volume":"86","author":"G Molyneux","year":"2005","unstructured":"Molyneux G, Gibson FM, Gordon-Smith EC, Pilling AM, Liu KC, Rizzo S et al (2005) The haemotoxicity of mitomycin in a repeat dose study in the female CD-1 mouse. Int J Exp Pathol 86(6):415\u2013430","journal-title":"Int J Exp Pathol"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-023-10210-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T18:16:34Z","timestamp":1685556994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-023-10210-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10210"],"URL":"https:\/\/doi.org\/10.1007\/s10585-023-10210-0","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"13 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors acknowledge the funding of the Dutch Cancer Society (project number 12055) and the support of the partners of Regenerative Medicine Crossing Borders (RegMed XB), powered by Health\u2009~\u2009Holland, Top Sector Life Sciences & Health and the Dutch Ministry of Education, Culture and Science for the Gravitation Programs (024.003.013 and 024.005.020). Patricia Dankers, Peter-Paul Fransen, and Geert van Almen are co-founders and hold shares of UPy-Ther BV. Ignace de Hingh receives an unrestricted research funding from Rand and ROCHE, both paid to the institute (Maastricht University).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements and disclosures"}}]}}